MCAS. The condition that makes everything worse and gets blamed for nothing.

Building it now.

GRAIN FREE ME — Medical Library

grainfreeme.com • Autoimmune & Inflammatory Category

Mast Cell Activation Syndrome

MCAS. The condition that makes everything worse and gets blamed for nothing.

I'm not a doctor. I'm not telling you to change your medication. Everything on this page is personal testimony and links to real medical sources. Always work with a qualified physician. Always ask for the right test by name.

What it is

Mast cells are immune cells. They live in tissue — skin, airways, gut lining, connective tissue — anywhere the body interfaces with the outside world. Their job is to be first responders. When they detect a threat — an allergen, a pathogen, physical damage — they activate and release a cascade of chemical mediators. Histamine is the most familiar one. Tryptase, prostaglandins, leukotrienes, cytokines — the list is long. The release is called degranulation, and it is supposed to be a targeted, proportional response to a real threat.

In mast cell activation syndrome, that system misfires. Mast cells activate and degranulate in response to triggers that should not be triggering them — foods, medications, temperature changes, exercise, stress, scents, vibration, pressure. Sometimes with no identifiable trigger at all. The response is disproportionate to whatever caused it, or it happens when nothing should have caused it, and the chemical cascade that follows touches every system those mast cells sit in.

Because mast cells live everywhere, MCAS produces symptoms everywhere. That is both its defining feature and the primary reason it takes so long to recognize. A condition that causes skin symptoms, GI symptoms, cardiovascular symptoms, neurological symptoms, and respiratory symptoms simultaneously — and differently on different days — does not fit neatly into any single specialist's lane. Each symptom gets routed to a different department. Nobody is looking at the whole picture.

MCAS is increasingly recognized as an underlying driver in ME/CFS, long COVID, and post-viral syndromes. The overlap is not coincidental. Mast cells are part of the innate immune system. Viral infections and immune dysregulation affect mast cell behavior. When the immune system is chronically dysregulated, mast cells are often part of what's misfiring.

Symptoms

The symptom picture in MCAS is wide, variable, and inconsistent — which is exactly what makes it so difficult to recognize and so easy to dismiss. Symptoms can vary dramatically day to day and trigger to trigger. A food that causes a significant reaction one day may be tolerated the next. This inconsistency is not fabrication. It is a feature of how mast cell activation actually behaves.

Skin:

• Flushing — sudden redness, particularly of the face, neck, and chest

• Hives (urticaria) — with or without an identifiable trigger

• Itching without visible rash

• Dermatographia — skin writing, where light pressure on the skin produces raised red lines

• Angioedema — swelling under the skin, particularly around the eyes, lips, and throat

Gastrointestinal:

• Nausea

• Abdominal cramping and pain

• Diarrhea

• Vomiting

• Bloating

• Symptoms that mimic IBS, Crohn's, or food intolerance and resist standard GI management

Cardiovascular:

• Heart palpitations

• Rapid heart rate (tachycardia)

• Low blood pressure, particularly upon standing — orthostatic hypotension

• Lightheadedness and near-syncope

• MCAS and POTS frequently co-occur — the overlap is common enough to be a clinical pattern

Respiratory:

• Nasal congestion and runny nose

• Wheezing

• Shortness of breath

• Throat tightness

Neurological:

• Brain fog — cognitive difficulty, word-finding problems, memory lapses

• Headache

• Anxiety — partly driven by the physiological effects of histamine and other mediators on the nervous system, not purely psychological

• Insomnia

Musculoskeletal:

• Muscle and joint pain

• Bone pain in mastocytosis, the related condition involving mast cell accumulation

The anaphylaxis end of the spectrum

Severe MCAS reactions can progress to anaphylaxis — a systemic, potentially life-threatening response involving multiple organ systems simultaneously. Not every MCAS patient reaches this end of the spectrum, but it is part of the disease picture and the reason epinephrine auto-injectors are prescribed to some MCAS patients. If you have had a reaction that involved throat tightening, significant blood pressure drop, or loss of consciousness — that conversation with your physician needs to happen before the next reaction.

The trigger problem

MCAS triggers are highly individual and inconsistent. What sets off one person's mast cells reliably may not affect another person at all. Within the same person, the same trigger may produce different responses depending on the total mast cell load at that moment — sometimes called the "bucket" concept. Multiple smaller triggers adding up can push the bucket over when any single trigger alone would not have.

Common trigger categories:

• Foods — particularly high-histamine foods (fermented foods, aged cheeses, alcohol, cured meats, certain fish), foods that release histamine (tomatoes, citrus, strawberries, spinach), and foods that block the enzyme that breaks down histamine (DAO inhibitors)

• Medications — NSAIDs, opioids, certain antibiotics, some contrast dyes, and others

• Temperature extremes — heat and cold both trigger mast cells in susceptible individuals

• Exercise — physical exertion as a trigger, distinct from post-exertional malaise in ME/CFS but sometimes overlapping

• Fragrances and chemical exposures — cleaning products, perfumes, smoke

• Emotional stress — direct physiological effect on mast cell behavior, not a dismissal of the condition as psychological

• Hormonal fluctuations — mast cells have estrogen receptors; many MCAS patients report symptoms that track with hormonal cycling

• Infections and post-viral states — viral infections can trigger or significantly worsen MCAS

The trigger inconsistency is one of the features that leads to dismissal. "You ate that last week with no problem" is not evidence against MCAS. It is a description of how MCAS works.

History and recognition

Mast cell disease has been recognized in its most severe form — systemic mastocytosis, where abnormal mast cells accumulate in organs — for over a century. MCAS as a distinct syndrome, separate from mastocytosis and from simple allergic disease, is considerably more recent.

The formal clinical criteria for MCAS were proposed in 2010 and refined in subsequent years. This is a young diagnostic category by medical standards, which explains both why many physicians are unfamiliar with it and why the diagnostic criteria have continued to evolve. Physicians who trained before MCAS was a defined entity may have limited familiarity with it as a clinical diagnosis, even if they routinely encounter patients who have it.

The significant increase in MCAS recognition in the context of long COVID has pushed the condition into broader medical awareness. A substantial body of evidence now supports mast cell activation as one of the documented mechanisms in long COVID — and that visibility has opened doors for ME/CFS and post-viral patients who have been carrying this diagnosis without a name for far longer.

The overlap with hypermobile Ehlers-Danlos Syndrome (hEDS) is another emerging clinical pattern — MCAS, POTS, and hEDS co-occurring in the same patient at rates well above what chance would predict. The triad has a name in clinical discussion now. Recognition is building. It is building late, but it is building.

Diagnosis

MCAS diagnosis requires demonstrating that mast cell mediators are elevated during symptomatic episodes, and that symptoms respond to treatments targeting mast cell activation.

The diagnostic challenge is real. Mast cell mediators are often released transiently during reactions and return to normal between episodes. Testing done when the patient is not in an active reaction may miss the elevation entirely. Timing of testing matters enormously.

The three-part diagnostic framework:

1. Symptoms consistent with mast cell mediator release affecting two or more organ systems

2. Laboratory evidence of elevated mast cell mediators during symptomatic periods

3. Response to treatment targeting mast cell activation

All three together build the diagnostic case.

Testing — ask for by name:

• Serum tryptase — the most stable mast cell mediator, but elevated baseline tryptase points more toward mastocytosis than MCAS. In MCAS, tryptase may be only transiently elevated during reactions. The key is serial measurement: tryptase drawn during a reaction compared to baseline tryptase at least 24 hours after reaction resolution. A rise of 20% plus 2 ng/mL above baseline is a diagnostic criterion. Tryptase during a reaction drawn within 15-60 minutes of symptom onset. Baseline tryptase at least 24 hours clear of symptoms.

• 24-hour urine N-methylhistamine — more stable than blood histamine and reflects ongoing mast cell activity over the collection period

• 24-hour urine prostaglandin D2 and 11β-prostaglandin F2α — prostaglandin mediators are produced by mast cells and measured in urine

• Plasma histamine — short half-life, requires careful handling and timing, less reliable than urine N-methylhistamine for most clinical purposes

• Bone marrow biopsy — required to rule out systemic mastocytosis when tryptase is consistently elevated or when clinical picture warrants. Not routine for MCAS evaluation without those indications.

The practical reality: collecting timed samples during an active reaction while symptomatic is harder than it sounds. Having the collection containers ready in advance — and a physician who has given specific instructions for what to collect and when — is the only way to capture the data that makes the diagnosis.

What you can do about it

MCAS has no cure. Management is aimed at reducing mediator release, blocking the effects of mediators that are released, and identifying and reducing trigger exposure.

Antihistamines — the first layer

H1 antihistamines (cetirizine, loratadine, fexofenadine, diphenhydramine) block histamine at H1 receptors — skin, airways, brain. H2 antihistamines (famotidine, ranitidine) block histamine at H2 receptors — primarily GI tract and cardiovascular. In MCAS management, using both H1 and H2 blockers together covers more of the histamine picture than either alone. This is standard MCAS practice, not an unusual combination.

Mast cell stabilizers

Cromolyn sodium — available as an oral formulation for GI MCAS symptoms — works by stabilizing mast cell membranes and reducing degranulation. It does not reverse a reaction in progress. It reduces the frequency and severity of activation when taken regularly before trigger exposure. Ketotifen is another mast cell stabilizer used in MCAS management, more available in some countries than others.

Prostaglandin and leukotriene blockade

Aspirin, in patients who tolerate it, can reduce prostaglandin production. Leukotriene receptor antagonists (montelukast) address the leukotriene branch of the mediator cascade. Whether these are appropriate for a specific patient depends on their individual trigger and mediator profile — and on whether they tolerate aspirin, since aspirin is itself an NSAID and a mast cell trigger in some MCAS patients.

Epinephrine auto-injector

If a physician has assessed that the severity of reactions warrants it, carrying an epinephrine auto-injector is part of MCAS management. This is a conversation to have explicitly with your treating physician — not to avoid, not to delay.

Low-histamine dietary approach

Reducing dietary histamine load — avoiding aged, fermented, and high-histamine foods — lowers the amount of histamine coming in from outside while the mast cells are producing their own internally. This is not a cure. It is reducing the input side of the bucket. For some MCAS patients it makes a meaningful difference in symptom burden. For others the dietary contribution is small relative to other triggers.

For the grain-free kitchen specifically: many standard low-histamine approaches require avoiding fermented foods, alcohol, and certain aged proteins. That part of the framework fits without conflict. The grain-containing foods on standard low-histamine lists are already eliminated here. Reading low-histamine food lists through a grain-free, HFI-aware lens takes some translation, but the overlap is workable.

Trigger identification and reduction

Keeping a detailed symptom and exposure log — foods, activities, environmental exposures, medications, stress events, hormonal timing — over time builds the individual trigger map that general MCAS resources cannot provide. No two MCAS patients have the same trigger profile. Finding yours is iterative and takes time.

The ME/CFS and post-viral overlap

This deserves its own space because the overlap is that significant.

ME/CFS patients have elevated mast cell mediators in documented research. Mast cells in the brain — microglia behave similarly — contribute to neuroinflammation. The post-exertional immune activation seen in ME/CFS and the mast cell degranulation cascade triggered by exercise in MCAS are not the same mechanism, but they interact. An ME/CFS patient with unrecognized MCAS is dealing with two separate sources of immune dysfunction simultaneously — and the combined load is worse than either alone.

In long COVID, mast cell activation is one of six documented pathological mechanisms identified in peer-reviewed research. The visibility that long COVID research has given to mast cell activation is genuinely useful for ME/CFS patients — the mechanism was already there. The funding and attention are new.

If you have ME/CFS or post-viral illness and your symptom picture includes significant flushing, hives, GI reactivity, orthostatic symptoms, and reactions to foods or environmental triggers — MCAS belongs in your differential. It is not the same as ME/CFS. It is not a replacement diagnosis. But it may be running alongside it, and treating the MCAS piece — even partially — can reduce the total symptom load enough to matter.

Personal note

I pulled this code during the diagnostic loop, and I pulled it carefully, because MCAS explains a lot of the picture that other diagnoses left on the table.

The flushing. The reactions to foods that aren't supposed to cause reactions. The way certain environmental exposures — specific cleaning products, specific fragrances — produce a systemic response that doesn't fit a simple allergy pattern. The way stress and exertion both have consequences that go beyond what fatigue alone explains.

I have not received a formal MCAS diagnosis. What I have is a consistent pattern of mediator-type symptoms in a person with ME/CFS, celiac, and HFI — all conditions that involve immune dysregulation — and a clinical picture that fits the MCAS framework well enough that I am not done with this question.

The mechanic's version: when multiple systems are throwing codes simultaneously and the codes don't fully explain each other, you look for the upstream sensor. MCAS may be an upstream sensor in my picture. The investigation is ongoing.

If you have an ME/CFS diagnosis, or a post-viral diagnosis, or any chronic inflammatory condition — and your symptom picture includes reactions that don't fit cleanly into what you already know — bring MCAS into the conversation with your physician. Ask specifically. Bring the symptom list. Ask about timed tryptase testing during a reaction. Ask about a trial of H1 and H2 antihistamine combination.

Push the question. The code is worth pulling.

Sources

• Afrin LB, et al. Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol. 2016. — PubMed PMID: 27112258

• Molderings GJ, et al. Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol. 2011. — PubMed PMID: 21418662

• Valent P, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012. — PubMed PMID: 22041891

• Theoharides TC, et al. Mast cells and inflammation. Biochim Biophys Acta. 2012. — PubMed PMID: 21185371

• Weinstock LB, et al. Mast cell activation syndrome as a cause of autonomic dysfunction. Clin Auton Res. 2021. — PubMed

• Weinstock LB, et al. Mast cell activation symptoms are prevalent in Long-COVID. Int J Infect Dis. 2023. — PubMed

• The Mastocytosis Society — tmsforacure.org

• NIH Genetic and Rare Diseases Information Center — rarediseases.info.nih.gov